Menu
← Oncology Approval Tracker
FDA DECISION ·
Koselugo
selumetinib · AstraZeneca Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas.
LAMPGEN ANALYSIS
Why it matters
Adult evidence supported extending this MEK inhibitor to patients with symptomatic benign tumors previously covered only by the pediatric indication.
What research teams should watch
Ensure adult NF1 referral networks can support volumetric imaging and ocular and cardiac assessments.
PRIMARY RECORDS